What make differences in the outcome of adjuvant treatments for resected gastric cancer?

doi:10.3748/wjg.v20.i33.11567

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 33

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6092)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

519

WORD

254

HTML

3209

Tables (1-3)

215

Sum=4197

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1044

Download

851

Sum=1895

Sep 7, 2014 (publication date) through Feb 1, 2025

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Sep 7, 2014; 20(33): 11567-11573
Published online Sep 7, 2014. doi: 10.3748/wjg.v20.i33.11567

Table 2 Postoperative adjuvant chemotherapy

Reporter/year	Regimens vs Surgery alone	Patients	OS 5ysr (%)
Reporter/year	Regimens vs Surgery alone	Patients	Treated	Control
Nakajima/1984	MFC + F/MF’C + F’	Curat. Res.	68.4/62.5	51.4
Coombes/1990	FAM	Curat. Res.	45.7	35.4
Krook/1991	FA	Curat. Res.	32	33
Macdonald/1995	FAM	I-III	37	32
Lise/1995	FAM2	II, III	42 mo¹	36 mo¹
Grau/1998	MMC + FT	Curat. Res.	67²	45
Nakajima/1999 (JACOG8801)	MF + UFT	S(+)	85.8	82.9
Neri/2001	ELF	N(+)	30.2²	12.6
Bajetta/2002	ELF	N(+)	52	48
Nashimoto/2003 (JCOG9206-1)	MFC + F	Curat. Res. S(-)	91.2	86.1
Chipponi/2004	FLP	S(+) or N(+)	39	39
Bouche/2005 (FFCD)	FP	II-IV	46.6	41.9
De Vita/2007 (GOIM 9602)	ELFE	IB-IIIB	48	43.5
Nakajima/2007 (NSAS-GC)	UFT	T2/N1−2	86²	73
Di Costanza/ 2008 (GOIRC)	PELF	IB-IV	47.6	48.7
Sasako/2011 (ACTS-GC)	S-1	II-III	71.7²	61.1
Miyashiro/2011	CDDPip + CFiv	S(+), curative	62	60.9
Noh/2013 (CLASSIC)	Cape. + Oxal.	II-IIIB	78²	69
Kang/2013 (AMC0201)	MMC + 5’FUDR (MF’) vs MF’ + CDDP	II-IV	61.1	57.9
Lee/2012 (ARTIST)	Cape. + CDDP(XP) vs XP + Rad. + XP	Curative, D2	78.2³	74.2

¹Median survival time (month);

²Statistically significant;

³Three year Disease free survival. OS 5ysr: Overall 5 year survival rate; MFC/F: Mitomycin C (MMC) + 5-FU + Cytosine arabinoside(CA) iv, and oral 5-FU; MF’C/F’: MMC + Ftoraful (FT) + CA iv and oral ftoraful; FAM: 5-FU + Adriamycin + MMC; FA: 5-FU + Adriamycin; FAM2: Modified 5-FU + Doxorubicin + MMC; MF+UFT: MMC + 5-FU iv and oral UFT; ELF: Etoposide + Leucovorin + 5-FU; FLP: 5-FU + Leucovorin + CDDP; FP: 5-FU + CDDP; ELFE: Epirubicin + Leucovorin + 5-FY + Etoposide; PELF: 5-FU + Leucovorin + CDDP + Epidoxorubicin; CDDPip + CFiv: CDDP ip + CDDP + 5-FU iv; S(+): Serosa involved; Curat. Res.: Curative resection.

Citation: Nakajima T, Fujii M. What make differences in the outcome of adjuvant treatments for resected gastric cancer? World J Gastroenterol 2014; 20(33): 11567-11573
URL: https://www.wjgnet.com/1007-9327/full/v20/i33/11567.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i33.11567